Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 29 of 29 results for ranibizumab

  1. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA409

  2. Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]

    In development [GID-TA11148] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  3. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    14 September 2022
    View recommendations

    Sections for TA824

  4. Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549

    Awaiting development [GID-TA11065] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...

    Research recommendation
    Published
    9 June 2015

  6. NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.

    further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema...

    Research recommendation
    Published
    9 June 2015

  7. Past appeals and decisions

    degeneration (age-related) - ranibizumab and pegaptanib 30 June 2008 TA237 Macular oedema (diabetic) - ranibizumab: appeal...

  8. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA229

  9. Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial growth factor (VEGF) treatment be suspended or stoppedin people with late AMD (wet)?

    inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs. People typically...

    Research recommendation
    Published
    13 November 2018

  10. Limited macular translocation for wet age-related macular degeneration (IPG339)

    Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

    Interventional procedures guidance
    Published
    19 May 2010
    View recommendations

    Sections for IPG339

  11. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Technology appraisal guidance
    Published
    30 November 2011

  12. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

    Medtech innovation briefing
    Published
    24 April 2018

  13. Research recommendations

    further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...

  14. Thousands of people in England could benefit after NICE recommends treatment option for two forms of sight loss

    NICE recommends faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema

    News
    Published
    24 May 2022